The glioblastoma multiforme (GBM) treatment market size has grown rapidly in recent years. It will grow from $2.48 billion in 2024 to $2.74 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increased incidence and prevalence, advancements in diagnostic techniques, clinical trials and research funding, collaborations and partnerships, improved understanding of tumor biology.
The glioblastoma multiforme (GBM) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.
The rising prevalence of brain disorders is anticipated to drive the growth of the glioblastoma multiforme (GBM) treatment market in the coming years. Brain disorders encompass the abnormal functioning of the brain, as well as the nerves throughout the body and the spinal cord. The growing incidence of brain disorders, including glioblastoma multiforme (GBM), is attributed to various factors such as an aging population, weakened immune systems, overdiagnosis, exposure to ionizing radiation, air pollution, and others. These factors contribute to the increasing demand for treatments aimed at improving well-being. For example, a report by the American Cancer Society, a US-based voluntary health organization focused on eliminating cancer, indicated that in 2022, approximately 25,050 cases of malignant tumors of the brain or spinal cord were diagnosed in the US. Therefore, the rising prevalence of brain disorders is a significant driver of growth in the glioblastoma multiforme (GBM) treatment market.
The glioblastoma multiforme (GBM) treatment market is expected to grow due to the rising geriatric population. The elderly, aged 65 and older, present specific health considerations, leading to the development of treatment strategies tailored for older patients with GBM. According to the World Health Organization, by 2030, 1 in 6 individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. This demographic shift is a key factor propelling the growth of the GBM treatment market.
Leading companies in the market are concentrating on developing innovative wearable and portable devices to maintain their competitive edge. These advancements aim to provide users with improved functionality, convenience, and comfort, addressing the increasing demand for accessible and efficient healthcare solutions. For example, in 2023, Novocure, an oncology company based in Jersey, introduced Optune Gio, a wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM), which has received FDA approval. This device utilizes Tumor Treating Fields (TTFields), which are alternating electric fields that interfere with cancer cell division, potentially enhancing patient survival. Weighing just 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during their daily activities.
Major companies are prioritizing innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves using radioactive substances to deliver targeted radiation to specific tissues or cells, commonly employed in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced the development of I-123 PARPi (THG-009) therapy. This innovative therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM) and is advancing to a Phase 1 clinical trial.
In April 2022, Elekta, a Sweden-based company providing radiation therapy, radiosurgery, related equipment, and clinical management for cancer treatment, signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals. This collaboration enables them to offer comprehensive solutions across imaging and treatment for cancer patients requiring radiation therapy. The partnership facilitates the joint promotion of solutions tailored to the needs of each cancer center.
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Glioblastoma multiforme (GBM) treatment involves the management and care of patients diagnosed with glioblastoma multiforme, a rapidly growing type of tumor located in the brain or spinal cord. This primary malignant brain tumor has the highest prevalence rate among adults.
The primary treatments for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor-treating field (TTF) therapy, and immunotherapy. Surgery is a medical discipline that concentrates on employing manual and instrumental methods to treat wounds, illnesses, and other conditions. The types of drugs involved in GBM treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered through oral, parenteral, and various other routes of administration and are used by hospitals, clinics, and ambulatory surgical centers.
The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The glioblastoma multiforme (GBM) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.
The rising prevalence of brain disorders is anticipated to drive the growth of the glioblastoma multiforme (GBM) treatment market in the coming years. Brain disorders encompass the abnormal functioning of the brain, as well as the nerves throughout the body and the spinal cord. The growing incidence of brain disorders, including glioblastoma multiforme (GBM), is attributed to various factors such as an aging population, weakened immune systems, overdiagnosis, exposure to ionizing radiation, air pollution, and others. These factors contribute to the increasing demand for treatments aimed at improving well-being. For example, a report by the American Cancer Society, a US-based voluntary health organization focused on eliminating cancer, indicated that in 2022, approximately 25,050 cases of malignant tumors of the brain or spinal cord were diagnosed in the US. Therefore, the rising prevalence of brain disorders is a significant driver of growth in the glioblastoma multiforme (GBM) treatment market.
The glioblastoma multiforme (GBM) treatment market is expected to grow due to the rising geriatric population. The elderly, aged 65 and older, present specific health considerations, leading to the development of treatment strategies tailored for older patients with GBM. According to the World Health Organization, by 2030, 1 in 6 individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. This demographic shift is a key factor propelling the growth of the GBM treatment market.
Leading companies in the market are concentrating on developing innovative wearable and portable devices to maintain their competitive edge. These advancements aim to provide users with improved functionality, convenience, and comfort, addressing the increasing demand for accessible and efficient healthcare solutions. For example, in 2023, Novocure, an oncology company based in Jersey, introduced Optune Gio, a wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM), which has received FDA approval. This device utilizes Tumor Treating Fields (TTFields), which are alternating electric fields that interfere with cancer cell division, potentially enhancing patient survival. Weighing just 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during their daily activities.
Major companies are prioritizing innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves using radioactive substances to deliver targeted radiation to specific tissues or cells, commonly employed in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced the development of I-123 PARPi (THG-009) therapy. This innovative therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM) and is advancing to a Phase 1 clinical trial.
In April 2022, Elekta, a Sweden-based company providing radiation therapy, radiosurgery, related equipment, and clinical management for cancer treatment, signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals. This collaboration enables them to offer comprehensive solutions across imaging and treatment for cancer patients requiring radiation therapy. The partnership facilitates the joint promotion of solutions tailored to the needs of each cancer center.
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Glioblastoma multiforme (GBM) treatment involves the management and care of patients diagnosed with glioblastoma multiforme, a rapidly growing type of tumor located in the brain or spinal cord. This primary malignant brain tumor has the highest prevalence rate among adults.
The primary treatments for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor-treating field (TTF) therapy, and immunotherapy. Surgery is a medical discipline that concentrates on employing manual and instrumental methods to treat wounds, illnesses, and other conditions. The types of drugs involved in GBM treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered through oral, parenteral, and various other routes of administration and are used by hospitals, clinics, and ambulatory surgical centers.
The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics3. Glioblastoma Multiforme (GBM) Treatment Market Trends and Strategies4. Glioblastoma Multiforme (GBM) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Glioblastoma Multiforme (GBM) Treatment Market34. Recent Developments in the Glioblastoma Multiforme (GBM) Treatment Market
5. Global Glioblastoma Multiforme (GBM) Treatment Growth Analysis and Strategic Analysis Framework
6. Glioblastoma Multiforme (GBM) Treatment Market Segmentation
7. Glioblastoma Multiforme (GBM) Treatment Market Regional and Country Analysis
8. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market
9. China Glioblastoma Multiforme (GBM) Treatment Market
10. India Glioblastoma Multiforme (GBM) Treatment Market
11. Japan Glioblastoma Multiforme (GBM) Treatment Market
12. Australia Glioblastoma Multiforme (GBM) Treatment Market
13. Indonesia Glioblastoma Multiforme (GBM) Treatment Market
14. South Korea Glioblastoma Multiforme (GBM) Treatment Market
15. Western Europe Glioblastoma Multiforme (GBM) Treatment Market
16. UK Glioblastoma Multiforme (GBM) Treatment Market
17. Germany Glioblastoma Multiforme (GBM) Treatment Market
18. France Glioblastoma Multiforme (GBM) Treatment Market
19. Italy Glioblastoma Multiforme (GBM) Treatment Market
20. Spain Glioblastoma Multiforme (GBM) Treatment Market
21. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market
22. Russia Glioblastoma Multiforme (GBM) Treatment Market
23. North America Glioblastoma Multiforme (GBM) Treatment Market
24. USA Glioblastoma Multiforme (GBM) Treatment Market
25. Canada Glioblastoma Multiforme (GBM) Treatment Market
26. South America Glioblastoma Multiforme (GBM) Treatment Market
27. Brazil Glioblastoma Multiforme (GBM) Treatment Market
28. Middle East Glioblastoma Multiforme (GBM) Treatment Market
29. Africa Glioblastoma Multiforme (GBM) Treatment Market
30. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape and Company Profiles
31. Glioblastoma Multiforme (GBM) Treatment Market Other Major and Innovative Companies
35. Glioblastoma Multiforme (GBM) Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on glioblastoma multiforme (gbm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for glioblastoma multiforme (gbm) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glioblastoma multiforme (gbm) treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Tumor Treating Field (TTF) Therapy; Immunotherapy2) By Drug Class: Temozolomide; Bevacizumab; Lomustine; Carmustine Wafers; Other Drug Classes
3) By Route of Administration: Oral; Parenteral; Other Route of Administrations
4) By End-Use: Hospitals; Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection; Biopsy Procedures2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy; Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors; Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors; Vaccine-Based Therapies
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- AstraZeneca PLC
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Jazz Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Oncology Inc.
- Varian Medical Systems Inc.
- Amneal Pharmaceuticals Inc.
- Elekta AB
- ANI Pharmaceuticals Inc.
- Accord Healthcare Limited
- The Eckert & Ziegler Group
- Loxo Oncology Inc.
- Karyopharm Therapeutics Inc.
- Celon Laboratories Pvt. Ltd.
- EnGeneIC Ltd.
- Zydus Pharmaceuticals Inc.
- Genenta Science S.r.l.
- Cantex Pharmaceuticals Inc.
- Vascular Biogenics Ltd.
- Seelos Therapeutics Inc
- Angiochem Inc.
- Diffusion Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.74 Billion |
| Forecasted Market Value ( USD | $ 4.1 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
